Pathstone Holdings’s X4 Pharmaceuticals XFOR Stock Holding History

Pathstone Holdings’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-421	Closed	-$2.99K	–	2349
2025 Q1	$2.99K	Hold	421	–	–	﹤0.01%	2222
2024 Q4	$9.27K	Hold	421	–	–	﹤0.01%	2297
2024 Q3	$8.46K	Hold	421	–	–	﹤0.01%	2324
2024 Q2	$7.33K	Hold	421	–	–	﹤0.01%	2301
2024 Q1	$17.6K	Hold	421	–	–	﹤0.01%	2285
2023 Q4	$10.6K	Buy	+421	New	+$10.2K	﹤0.01%	2192

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pathstone Holdings's XFOR Position: Q2 2025 in Review

Pathstone Holdings sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 421 shares — an estimated $2.99K sold.

Pathstone Holdings first reported a position in XFOR in Q4 2023 and held it in 6 quarters. The position peaked at $17.6K in Q1 2024. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

Pathstone Holdings reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Pathstone Holdings sold 421 X4 Pharmaceuticals shares in Q2 2025, an estimated $2.99K.
Pathstone Holdings first reported a position in X4 Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Pathstone Holdings's X4 Pharmaceuticals position peaked at $17.6K in Q1 2024.
51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on Pathstone Holdings's 13F filing for Q2 2025, filed 12 Aug 2025.